Biology

Weekly News Round-up – 13/3/20

4 months ago By Josh Neil
  • Share on

  • Facebook
  • Linkedin
Proventa International Weekly News

Despite coronavirus’ new pandemic status and the number of new cases tied with Biogen’s conference in late February, today’s news really won’t discuss coronavirus, apart from this first sentence. In the news this week, among other things the UK’s latest budget has introduced a number of pharma-friendly proposals; Amgen/Allergan’s Rituximab biosimilar looks set to be a blockbuster; and the FDA halts overseas inspections due to certain flu-related, topical reasons. 

UK BUDGET INTRODUCES PHARMA-FRIENDLY MEASURES – UK Chancellor Rishi Sunak has delivered his first budget this week. Alongside the £5 billion set aside to aid the NHS, the UK government intends to increase R&D tax credits from 12% to 13%, raising investment to £22 billion a year. The BioIndustry Association also received a £200 million ‘scale-up fund’ for life sciences. It will now look to secure a further £400 million in private investment. 

NICE ACCEPTS TEVA’S MIGRAINE DRUG AJOVY AFTER REJECTING NOVARTIS RIVAL – Following its rejection of NHS funding for Novartis’ CGRP inhibitor Aimovig, NICE has backed rival Teva’s migraine prevention drug Ajovy. NICE said Teva had offered a discount on its £5,000 a year price list, bringing it under the threshold for cost-effectiveness. Following an outcry about Aimovig’s rejection, NICE is set to review its decision. The rejection also creates a disparity, as Aimovig was accepted for Scottish NHS use in April 2019. 

AMGEN/ALLERGAN RITUXIMAB BIOSIMILAR COULD BE BLOCKBUSTER – Amgen/Allergan’s cancer drug biosimilar is one of ten possible blockbuster drugs by 2025, data firm GlobalData has suggested. The drug, a near-copy of Roche’s rituximab, could reach up to $4 billion in sales by that year.

In other news: 

R&D
Janssen’s lung cancer dual-target antibody could be a Breakthrough Therapy

Clinical Trials
BMS/Abbvie multiple myeloma combo fails in trials

Manufacturing
FDA halts foreign inspections over COVID-19 virus

That’s all for now. See you next week!

Joshua Neil, Editor
Proventa International

To ensure you remain up-to-date on the latest in clinical development, sign up for Proventa International’s online Clinical Operations, Supply Chain & Pharmacovigilance Strategy Meeting 2020.

More news

The Medicinal Chemist Role in the World of AI

Over the last few decades, the field of medicinal chemistry has been significantly changed by major innovations such as the internet and, more recently, automation. These changes have all driven the area towards quicker and more cost-effective medicinal chemistry, focused...

2 months ago
Biology

The Medicinal Chemist Role in the World of AI

Over the last few decades, the field of medicinal chemistry has been significantly changed by major innovations such as the internet and, more recently, automation. These changes have all driven the area towards quicker and more cost-effective medicinal chemistry, focused...

2 months ago

R&D: The Impact of AI in 2020

Whenever Proventa holds a Strategy Meeting around the world - regardless of meeting topic - the subject of AI comes up. It really is so important in pharma right now, with the potential to solve some of the sector's big...

4 months ago
Biology

R&D: The Impact of AI in 2020

Whenever Proventa holds a Strategy Meeting around the world - regardless of meeting topic - the subject of AI comes up. It really is so important in pharma right now, with the potential to solve some of the sector's big...

4 months ago

Weekly News Round-up – 14/2/20

The U.S. Institute for Clinical and Economic Review’s (ICER’s) methods could see legal challenges in the near future, a think tank has warned, due to discrimination against disabled individuals. In other news, Novartis’ rare lung cancer drug capmatinib will be...

5 months ago
Biology

Weekly News Round-up – 14/2/20

The U.S. Institute for Clinical and Economic Review’s (ICER’s) methods could see legal challenges in the near future, a think tank has warned, due to discrimination against disabled individuals. In other news, Novartis’ rare lung cancer drug capmatinib will be...

5 months ago
Working With us

Interested?
Reserve your space